emodepside
Small moleculeexperimental
Emodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively new class of anthelmintic, which are suspected to achieve their anti-parasitic effect by a novel mechanism of action due to their ability to kill nematodes resistant to other anthelmintics. — Wikipedia
Clinical trial activity
10 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02661178)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H]1C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N1C- Mol. weight
- 1119.41 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmodepside ↗
- ChEMBLCHEMBL2104404 ↗
Also known as
- emodepside
- emodepside
- emodepside
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07258173 | Phase 2 | Jan 15, 2026 | Bayer, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS), University of Basel |
| NCT06800248 | Phase 3 | Aug 31, 2025 | Bayer, Silicon Valley Community Foundation, University of Basel, University of the Philippines |
| NCT06736691 | Phase 3 | May 31, 2025 | Bayer, Silicon Valley Community Foundation, University of Basel |
| NCT06373835 | Phase 2 | May 20, 2024 | Government of Laos, University of Basel |
| NCT05538767 | Phase 2 | Sep 16, 2022 | University of Basel |
| NCT05180461 | Phase 2 | Aug 30, 2021 | Bayer, Drugs for Neglected Diseases Initiative |
| NCT05017194 | Phase 2 | Aug 15, 2021 | University of Basel |
| NCT03383614 | Phase 1 | Nov 10, 2017 | Bayer, Bill and Melinda Gates Foundation, Drugs for Neglected Diseases Initiative, Hammersmith Medicines Research |
| NCT03383523 | Phase 1 | Oct 30, 2017 | Bayer, Bill and Melinda Gates Foundation, Drugs for Neglected Diseases Initiative, Hammersmith Medicines Research |
| NCT02661178 | Phase 1 | Dec 1, 2015 | Bayer, Bill and Melinda Gates Foundation, Drugs for Neglected Diseases Initiative, Hammersmith Medicines Research |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 7 | 0 | 3 | 2015 |
| University of Basel | Academic/Hospital | 6 | 6 | 2 | 2021 |
| Drugs for Neglected Diseases Initiative | Academic/Hospital | 4 | 4 | 2 | 2015 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Hammersmith Medicines Research | For profit | 3 | 0 | 1 | 2015 |
| Silicon Valley Community Foundation | Academic/Hospital | 2 | 0 | 1 | 2025 |
| Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS) | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Government of Laos | Government | 1 | 0 | 1 | 2024 |
| University of the Philippines | Academic/Hospital | 1 | 0 | 1 | 2025 |
9 organizations
Page 1 / 1